Tien Le
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tien Le has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
L. Hopkins
10 shared publicationsM. Fung Kee Fung
7 shared publicationsLaura Hopkins
6 shared publicationsW. Faught
Department of Obstetrics, Gynecology and Newborn Care, Division of Gynecologic Oncology, University of Ottawa, Ottawa, Ontario, Canada
6 shared publicationsWylam Faught
6 shared publicationsM. Fung-Kee-Fung
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Ontario, Canada
4 shared publications
Latest Publications
- 6 August 2013
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 33 (6) , 622-625
Loop electrosurgical excision procedure for the treatment of cervical intraepithelial neoplasia: How much excision is enough?
This is a retrospective observational study to compare outcomes in patients with cervical intraepithelial neoplasia (CIN) treated with loop electrosurgical excision procedure (LEEP) using combined ectocervical/endocervical resection vs ectocervical resection alone. We demonstrated that additional endocervical resection during loop electrosurgical excision procedure did not significantly lower the risk of subsequent recurrence compared with ectocervical resection alone, in the treatment of CIN. With current published data supporting subsequent increased adverse effects of LEEP on future obstetrical outcomes, endocervical excision should be applied selectively. We recommend that additional endocervical excision should be reserved only for patients with a strong suspicion of underlying endocervical canal involvement based on colposcopic assessment or in patients with unsatisfactory colposcopy, where it is essential to evaluate the endocervical canal.
- 6 August 2013
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 33 (6) , 622-625
Loop electrosurgical excision procedure for the treatment of cervical intraepithelial neoplasia: How much excision is enough?
This is a retrospective observational study to compare outcomes in patients with cervical intraepithelial neoplasia (CIN) treated with loop electrosurgical excision procedure (LEEP) using combined ectocervical/endocervical resection vs ectocervical resection alone. We demonstrated that additional endocervical resection during loop electrosurgical excision procedure did not significantly lower the risk of subsequent recurrence compared with ectocervical resection alone, in the treatment of CIN. With current published data supporting subsequent increased adverse effects of LEEP on future obstetrical outcomes, endocervical excision should be applied selectively. We recommend that additional endocervical excision should be reserved only for patients with a strong suspicion of underlying endocervical canal involvement based on colposcopic assessment or in patients with unsatisfactory colposcopy, where it is essential to evaluate the endocervical canal.
- 1 June 2011
- Published by Elsevier in Gynecologic Oncology
- Vol. 121 (3) , 451-454
Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
- 1 June 2011
- Published by Elsevier in Gynecologic Oncology
- Vol. 121 (3) , 451-454
Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
- 18 January 2011
- Published by IGI Global Scientific Publishing
Informatics and Ovarian Cancer Care
Informatics and Ovarian Cancer Care: 10.4018/978-1-60566-078-3.ch012: Ovarian cancer affects 2,400 women annually in Canada with a case fatality ratio of 0.70. There are several practice guidelines that indicate women with early
- 18 January 2011
- Published by IGI Global Scientific Publishing
Informatics and Ovarian Cancer Care
Informatics and Ovarian Cancer Care: 10.4018/978-1-60566-078-3.ch012: Ovarian cancer affects 2,400 women annually in Canada with a case fatality ratio of 0.70. There are several practice guidelines that indicate women with early
- 1 November 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 75 (3) , 795-802
Longitudinal Assessments of Quality of Life in Endometrial Cancer Patients: Effect of Surgical Approach and Adjuvant Radiotherapy
- 1 November 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 75 (3) , 795-802
Longitudinal Assessments of Quality of Life in Endometrial Cancer Patients: Effect of Surgical Approach and Adjuvant Radiotherapy
- 1 May 2008
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 18 (3) , 428-431
Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer
- 1 May 2008
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 18 (3) , 428-431
Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer
- 1 September 2007
- Published by Elsevier in Gynecologic Oncology
- Vol. 106 (3) , 579-584
Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia
- 1 September 2007
- Published by Elsevier in Gynecologic Oncology
- Vol. 106 (3) , 579-584
Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia
- 1 July 2007
- Published by Elsevier in Gynecologic Oncology
- Vol. 106 (1) , 160-163
Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking
- 1 July 2007
- Published by Elsevier in Gynecologic Oncology
- Vol. 106 (1) , 160-163
Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking
- 12 June 2007
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 14 (9) , 2649-2653
Omental Chemotherapy Effects as a Prognostic Factor in Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy and Delayed Primary Surgical Debulking
We sought to assess the prognostic significance of chemotherapy effect on upper abdominal metastatic disease. Retrospective chart reviews were carried out from 1997 to 2005 to identify ovarian cancer patients treated with neoadjuvant chemotherapy. Pathologic examinations of resected omental and ovarian tumors for the presence of chemotherapy effect were performed. Cox proportional hazard models were built to model time to progression and death by using predictor variables of age, tumor grade, amount and location of largest residual disease, and the presence of chemotherapy effects on resected tumors. Sixty-six patients with available slides and clinical information were identified. The presence of omental chemotherapy effects was observed in 58 patients (88%). Identified independent statistically significant predictors for progression-free survival included presence of omental chemotherapy effect (hazard ratio [HR], .38; 95% confidence interval [95% CI], .17-.89; P = .026) and suboptimal tumor residuals in upper abdominal location compared with pelvic location (HR, 2.41; 95% CI, 1.06-5.48; P = .035). The presence of omental chemotherapy effect was the only statistically significant predictor of disease specific survival (HR, .21; 95% CI, .068-.639; P = .006). The estimated median survival for the group with positive omental chemotherapy effect was 84.45 months (95% CI, 69.63-99.28). The corresponding statistic in patients with no observed response to chemotherapy was 31.15 months (95% CI, 21.84-40.47). Upper abdominal disease location and its response to chemotherapy were independent prognostic factors for progression-free survival. Aggressive upper abdominal debulking procedures are recommended to improve oncologic outcomes.
- 12 June 2007
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 14 (9) , 2649-2653
Omental Chemotherapy Effects as a Prognostic Factor in Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy and Delayed Primary Surgical Debulking
We sought to assess the prognostic significance of chemotherapy effect on upper abdominal metastatic disease. Retrospective chart reviews were carried out from 1997 to 2005 to identify ovarian cancer patients treated with neoadjuvant chemotherapy. Pathologic examinations of resected omental and ovarian tumors for the presence of chemotherapy effect were performed. Cox proportional hazard models were built to model time to progression and death by using predictor variables of age, tumor grade, amount and location of largest residual disease, and the presence of chemotherapy effects on resected tumors. Sixty-six patients with available slides and clinical information were identified. The presence of omental chemotherapy effects was observed in 58 patients (88%). Identified independent statistically significant predictors for progression-free survival included presence of omental chemotherapy effect (hazard ratio [HR], .38; 95% confidence interval [95% CI], .17-.89; P = .026) and suboptimal tumor residuals in upper abdominal location compared with pelvic location (HR, 2.41; 95% CI, 1.06-5.48; P = .035). The presence of omental chemotherapy effect was the only statistically significant predictor of disease specific survival (HR, .21; 95% CI, .068-.639; P = .006). The estimated median survival for the group with positive omental chemotherapy effect was 84.45 months (95% CI, 69.63-99.28). The corresponding statistic in patients with no observed response to chemotherapy was 31.15 months (95% CI, 21.84-40.47). Upper abdominal disease location and its response to chemotherapy were independent prognostic factors for progression-free survival. Aggressive upper abdominal debulking procedures are recommended to improve oncologic outcomes.
- 1 June 2007
- Published by Elsevier in Gynecologic Oncology
- Vol. 105 (3) , 712-715
The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking
- 1 June 2007
- Published by Elsevier in Gynecologic Oncology
- Vol. 105 (3) , 712-715
The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking